Wendy L Havran, 1955-2020 | With heavy hearts, we mourn the sudden passing of a very dear friend on January 20, 2020 | An exceptional scientist | A mentor to all | A community leader | A warm generous personality | A grande dame always | @ScrippsResearch | #WeMissYouWendy

The latest story from our lab describing the detrimental effects of extracelluar ISG15 in the lungs during viral infection is on BioRxiv now! Congratulations to our postdoc Namir Shaabani, who is the first author! Check it out here: biorxiv.org/content/10.110…

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model dlvr.it/RWT6RM

Tour de force!

Great collaborative effort! #ScrippsResearch #IAVI #UCSD Find the paper here: science.sciencemag.org/content/early/…

Great day for the lab! Our collaborative work with Luke Larson's lab and Calibr came out today in Science! Congratulations to Vincent, Emily, Ying, and the whole team! We identified and characterized a novel, anti-tumor STING agonist, SR-717. Read it here: science.sciencemag.org/content/sci/36…

Great example of basic research at Scripps and the Calibr drug discovery engine coming together to advance medicines for human disease. Watch this space. Congrats to all involved!

Merry Christmas and Happy Holidays from all of us in the Teijaro Lab!

COVID-19 vaccines: modes of immune activation and future challenges dlvr.it/Rv2JRr

Congratulations to Erica OllmannSaphire on being newly appointed as President and CEO La Jolla Institute. A former graduate student and accomplished faculty member at Scripps Research, we wish her much success in her continued leadership in immunology and virology.

Check out the review by Chris Parker from Scripps Research on the integration #phenotypic #screening and #chemoproteomics, in particular using chemoproteomic-enabled libraries to streamline the #drug #discovery process dlvr.it/RvyymJ

Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy biorxiv.org/content/10.110…

Excited to share work with our lab and Parker lab Chris Parker on the development and characterization of the first Slc15a4 inhibitors. biorxiv.org/content/10.110…

Humbled to be a part of this newest venture with great colleagues Ben Cravatt, Chris Parker and Stuart Schreiber. Looking forward to what lies ahead!

Excited to share the final version in Nature Chemical Biology. Lots more mechanistic insights & characterization, including our inhibitors disrupt PPIs with mTOR components & induce lysosomal degradation of SLC15A4, & more. A promising target for autoimmune conditions. nature.com/articles/s4158…

nature.com/articles/s4158… Pleased to see this one in print. What a journey with the parker lab Chris Parker! Great example of merging chemical biology and immunology to generate an exciting tool to probe the immune response. Congrats to everyone involved and all the hard work!!

Proud of my two post-docs on their Science paper demonstrating JAK inhibitors can promote better anti-tumor responses in combination with checkpoint immunotherapy. Well done Jerry and Isa as well as all the authors! Special thanks to Dr. Veronika Bachanova for running the trial!

JAK inhibitors enhance anti–PD-1 immunotherapy by modulating T cell exhaustion and inflammatory signaling, as shown in preclinical models and clinical trials for non-small cell lung cancer and Hodgkin lymphoma.science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… #NBThighlight

Congrats to everyone involved. Andy Minn, E. John Wherry, Divij, Jerry Zak and Isa. Two great complimentary studies that hopefully will catalyze better treatments for patients in need soon! 👏

Dysregulated ISG15 production and signaling during persistent LCMV infection drives lethal immune pathology, representing a therapeutic target during severe viral infections with pulmonary manifestations The Journal of Immunology Namir Shaabani Teijaro Lab doi.org/10.4049/jimmun…